Trade IMVT anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Immunovant, Inc. (IMVT) is trading at US$41.90, down 4.38% today as of Aug 28, 12:22 EDT. The company has a market capitalisation of US$9.16B. Over the past 52 weeks, IMVT has traded between US$14.47 and US$45.42. On Syfe you can trade IMVT with $0 commission and add it to your watchlist.
| Previous close | US$43.82 |
|---|---|
| Market cap | US$9.16B |
| 52-week range | US$14.47 – US$45.42 |
| Volume | 667.02K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Immunovant, Inc.
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It develops a novel, fully human monoclonal antibody, IMVT-1401, which selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded on July 6, 2018 and is headquartered in Durham, NC.
Year: 2019
Immunovant Insider Sold Shares Worth $263,015, According to a Recent SEC Filing
Jul 27, 8:01 AM · MT Newswires
Immunovant, Inc. (IMVT) stock is trading at US$41.90, -4.38% from the previous close of US$43.82.
The market cap for Immunovant, Inc. (IMVT) stock is approximately US$9.16B.
The 52-week high for Immunovant, Inc. (IMVT) stock is US$45.42.
The 52-week low for Immunovant, Inc. (IMVT) stock is US$14.47.
Immunovant, Inc. (IMVT) does not currently pay a dividend.
Stay on top of IMVT
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
